Pulmonx Corporation (LUNG) reported fourth-quarter 2025 revenue of $22.6 million, down 4.9% year over year. Gross profit was $17.5 million, essentially flat, down 0.3% year over year. Cost of sales declined to $5.1 million, down 18.1% year over year.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Pulmonx Corporation Insider Trading Activity
Pulmonx Corporation insiders have traded $LUNG stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.
Here’s a breakdown of recent trading of $LUNG stock by insiders over the last 6 months:
- GLENDON E. III FRENCH (President and CEO) has made 0 purchases and 5 sales selling 76,618 shares for an estimated $110,796.
- DANIEL P FLORIN sold 23,321 shares for an estimated $46,408
- DAVID AARON LEHMAN (GENERAL COUNSEL) has made 0 purchases and 8 sales selling 22,515 shares for an estimated $33,635.
- GEOFFREY BERAN ROSE (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 8 sales selling 14,054 shares for an estimated $20,982.
- SRIKANTH RADHAKRISHNAN (Chief Science &Techn. Officer) has made 0 purchases and 4 sales selling 10,483 shares for an estimated $14,990.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Pulmonx Corporation Hedge Fund Activity
We have seen 48 institutional investors add shares of Pulmonx Corporation stock to their portfolio, and 77 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 2,099,156 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $4,639,134
- SOLEUS CAPITAL MANAGEMENT, L.P. added 2,038,323 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,504,693
- EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,951,173 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,312,092
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,890,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,061,800
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. removed 1,168,513 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,892,991
- KENT LAKE PR LLC added 926,157 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,500,374
- VESTAL POINT CAPITAL, LP removed 830,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,834,300
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Pulmonx Corporation Government Contracts
We have seen $168,365 of award payments to $LUNG over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ZEPHR VALVES: $22,414
- PROSTHETICS:IMPLANT: $20,281
- PROS - BILL ONLY - BRONCHOSCOPY: $18,840
- CUSTOM SURGICAL IMPLANTS: $17,940
- PULMONARY PROSTHETIC: $14,950
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Pulmonx Corporation Analyst Ratings
Wall Street analysts have issued reports on $LUNG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- D. Boral Capital issued a "Buy" rating on 11/13/2025
To track analyst ratings and price targets for Pulmonx Corporation, check out Quiver Quantitative's $LUNG forecast page.
Pulmonx Corporation Price Targets
Multiple analysts have issued price targets for $LUNG recently. We have seen 3 analysts offer price targets for $LUNG in the last 6 months, with a median target of $5.0.
Here are some recent targets:
- Jon Young from Canaccord Genuity set a target price of $5.0 on 03/05/2026
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 03/05/2026
- Frank Takkinen from Lake Street set a target price of $4.0 on 10/28/2025
